Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

doi:10.1038/nature14119

Title: Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Full Record
Other Related Research

Authors:

Pemovska, Tea; Johnson, Eric; Kontro, Mika; Repasky, Gretchen A.; Chen, Jeffrey; Wells, Peter; Cronin, Ciarán N.; McTigue, Michele; Kallioniemi, Olli; Porkka, Kimmo; Murray, Brion W.; Wennerberg , Krister ^[1]; Helsinki) ^[2]

(Pfizer)
(

Publication Date:: 2015-09-29

Research Org.:: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)

Sponsoring Org.:: FOREIGN

OSTI Identifier:: 1194216

Resource Type:: Journal Article

Journal Name:: Nature

Additional Journal Information:: Journal Volume: 519; Journal Issue: 03, 2015

Country of Publication:: United States

Language:: ENGLISH

Citation Formats


                    Pemovska, Tea, Johnson, Eric, Kontro, Mika, Repasky, Gretchen A., Chen, Jeffrey, Wells, Peter, Cronin, Ciarán N., McTigue, Michele, Kallioniemi, Olli, Porkka, Kimmo, Murray, Brion W., Wennerberg , Krister, and Helsinki). Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.  United States: N. p., 2015. 
        Web.  doi:10.1038/nature14119.

Copy to clipboard


                    Pemovska, Tea, Johnson, Eric, Kontro, Mika, Repasky, Gretchen A., Chen, Jeffrey, Wells, Peter, Cronin, Ciarán N., McTigue, Michele, Kallioniemi, Olli, Porkka, Kimmo, Murray, Brion W., Wennerberg , Krister, & Helsinki). Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.  United States.  doi:10.1038/nature14119.

Copy to clipboard


                    Pemovska, Tea, Johnson, Eric, Kontro, Mika, Repasky, Gretchen A., Chen, Jeffrey, Wells, Peter, Cronin, Ciarán N., McTigue, Michele, Kallioniemi, Olli, Porkka, Kimmo, Murray, Brion W., Wennerberg , Krister, and Helsinki). Tue .  
        "Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation".  United States.  doi:10.1038/nature14119.

Copy to clipboard


                    
@article{osti_1194216,

  title        = {Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation},

  author       = {Pemovska, Tea and Johnson, Eric and Kontro, Mika and Repasky, Gretchen A. and Chen, Jeffrey and Wells, Peter and Cronin, Ciarán N. and McTigue, Michele and Kallioniemi, Olli and Porkka, Kimmo and Murray, Brion W. and Wennerberg , Krister and Helsinki)},

  abstractNote = {},

  doi          = {10.1038/nature14119},

  journal      = {Nature},
number       = 03, 2015,

  volume       = 519,

  place        = {United States},

  year         = {2015},

  month        = {9}

}

Copy to clipboard

Journal Article:

DOI: 10.1038/nature14119

Other availability

Find in Google Scholar

Search WorldCat to find libraries that may hold this journal

Save / Share:

Export Metadata

Save to My Library

Similar records in OSTI.GOV collections:

Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

Journal Article Zhou, Tianjun ; Commodore, Lois ; Huang, Wei-Sheng ; ... - Chem. Biol. Drug Des.

The BCR-ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia. However, drug resistance caused by kinase domain mutations has necessitated the development of new mutation-resistant inhibitors, most recently against the T315I gatekeeper residue mutation. Ponatinib (AP24534) inhibits both native and mutant BCR-ABL, including T315I, acting as a pan-BCR-ABL inhibitor. Here, we undertook a combined crystallographic and structure-activity relationship analysis on ponatinib to understand this unique profile. While the ethynyl linker is a key inhibitor functionality that interacts with the gatekeeper, virtually all other components of ponatinib play an essential role in its T315I inhibitory activity. The extensive networkmore »« less
DOI: 10.1111/j.1747-0285.2010.01054.x
SGX393 inhibits the CML mutant Bcr-Abl[superscript T315I] and preempts in vitro resistance when combined with nilotinib or dasatinib

Journal Article O'Hare, Thomas ; Eide, Christopher A. ; Tyner, Jeffrey W. ; ... - Proc. Natl. Acad. Sci. USA

Imatinib inhibits Bcr-Abl, the oncogenic tyrosine kinase that causes chronic myeloid leukemia. The second-line inhibitors nilotinib and dasatinib are effective in patients with imatinib resistance resulting from Bcr-Abl kinase domain mutations. Bcr-Abl{sup T315I}, however, is resistant to all Abl kinase inhibitors in clinical use and is emerging as the most frequent cause of salvage therapy failure. SGX393 is a potent inhibitor of native and T315I-mutant Bcr-Abl kinase that blocks the growth of leukemia cell lines and primary hematopoietic cells expressing Bcr-Abl{sup T315I}, with minimal toxicity against Bcr-Abl-negative cell lines or normal bone marrow. A screen for Bcr-Abl mutants emerging inmore »« less
DOI: 10.1073/pnas.0800587105
Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template

Journal Article Zhou, Tianjun ; Commodore, Lois ; Huang, Wei-Sheng ; ... - Chem. Biol. Drug Des.

Bcr-Abl is the oncogenic protein tyrosine kinase responsible for chronic myeloid leukemia (CML). Treatment of the disease with imatinib (Gleevec) often results in drug resistance via kinase mutations at the advanced phases of the disease, which has necessitated the development of new mutation-resistant inhibitors, notably against the T315I gatekeeper mutation. As part of our efforts to discover such mutation resistant Abl inhibitors, we have focused on optimizing purine template kinase inhibitors, leading to the discovery of potent DFG-in and DFG-out series of Abl inhibitors that are also potent Src inhibitors. Here we present crystal structures of Abl bound by twomore »« less
DOI: 10.1111/j.1747-0285.2009.00905.x
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

Journal Article OHare, Thomas ; Shakespeare, William C. ; Zhu, Xiaotian ; ... - Cancer Cell

Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain mutations can lead to relapse and a switch to second-line therapy with nilotinib or dasatinib. Despite three approved therapeutic options, the cross-resistant BCR-ABL{sup T315I} mutation and compound mutants selected on sequential inhibitor therapy remain major clinical challenges. We report design and preclinical evaluation of AP24534, a potent, orally available multitargeted kinase inhibitor active against T315I and other BCR-ABL mutants. AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABL{sup T315I}-driven tumor growth in mice, andmore »« less
DOI: 10.1016/j.ccr.2009.09.028
Use of iron-meso-tetra-(4-sulfonatophenyl)-porphine (FeTPPS) to examine hemopexin-mediated heme transport

Journal Article Tatum, F.M. ; Morgan, W.T. ; Burch, M.K. ; ... - Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States)

Hemopexin (HPX) alters conformation upon binding heme as shown by circular dichroism (CD) while FeTPPS binds without changes in the CD spectrum . Therefore, FeTPPS was used to examine the importance of changes in HPX conformation for receptor binding and for HPX-mediated heme transport. FeTPPS-HPX binds to the HPX receptor on mouse hepatoma Hepa cells but with lower affinity then heme-HPX. Incubation of cells with 50 nM heme-/sup 125/I-HPX after 2.5 ..mu..M heme- or FeTPPS-HPX decreased binding from 0.34 pmol/mg protein to 0.10 and 0.27, respectively. Preincubation with 2.5 ..mu..M apoHPX reduced binding to the same extent as FeTPPS-HPX indicatingmore »« less

Similar Records